ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ANBL19P1: Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Protocol ID
ANBL19P1
Condition/s
Ganglioneuroblastoma, Nodular
Neuroblastoma
Diagnosis Stage
New Diagnosis
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
up to 30 Years
International registry ID's
NCT04385277
Back to Registry
Study Title ANBL19P1: Pilot Study of Dinutuximab Sargramostim (GM-CSF) and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Protocol ID ANBL19P1
Disease (Sub Disease) Ganglioneuroblastoma, Nodular
Neuroblastoma
Diagnosis Stage New Diagnosis
Sponsor Children's Oncology Group
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT04385277
Trial Status Closed to Recruitment
Trial Open Date 30/11/2020
Study Type Treatment
Phase Pilot
Age Eligibility up to 30 Years
International registry ID's NCT04385277

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.